| Literature DB >> 33611770 |
Anvay Ukidve1,2, Katharina Cu1,2, Ninad Kumbhojkar1,2, Joerg Lahann3, Samir Mitragotri4,5.
Abstract
Cancer immunotherapy has been at the forefront of therapeutic interventions for many different tumor types over the last decade. While the discovery of immunotherapeutics continues to occur at an accelerated rate, their translation is often hindered by a lack of strategies to deliver them specifically into solid tumors. Accordingly, significant scientific efforts have been dedicated to understanding the underlying mechanisms that govern their delivery into tumors and the subsequent immune modulation. In this review, we aim to summarize the efforts focused on overcoming tumor-associated biological barriers and enhancing the potency of immunotherapy. We summarize the current understanding of biological barriers that limit the entry of intravascularly administered immunotherapies into the tumors, in vitro techniques developed to investigate the underlying transport processes, and delivery strategies developed to overcome the barriers. Overall, we aim to provide the reader with a framework that guides the rational development of technologies for improved solid tumor immunotherapy.Entities:
Keywords: Adoptive cell transfer; Biomaterials; Immune modulation; Immunotherapy; Nanoparticles; Solid tumor
Mesh:
Year: 2021 PMID: 33611770 DOI: 10.1007/s13346-021-00923-8
Source DB: PubMed Journal: Drug Deliv Transl Res ISSN: 2190-393X Impact factor: 4.617